Autolus Therapeutics plc - American Depositary Shares (AUTL) earnings
AUTL earnings moved a median of +0.65% by the close. Quarterly and annual AUTL reports and results, each read against the price at its own news timestamp. Back to the AUTL overview →
33 measured AUTL earnings events.
Where these AUTL earnings landedvs 31 measured AUTL earnings reactions
| Middle 50% of AUTL earnings reactions | -3.33% to +2.83% |
|---|---|
| Median reaction (to close) | +0.65% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 AUTL earnings events with a measured close landed between -3.33% and +2.83%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | Press release | +3.92% | +14.22% | |
| Form 10-Q Autolus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +1.28% | -9.40% | |
| Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors | Press release | -5.23% | +5.81% | |
| Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 | Press release | +4.97% | +7.74% | |
| Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | Press release | -4.49% | +1.92% | |
| Form 10-Q Autolus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.63% | +3.17% | |
| Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 | Press release | +0.63% | +2.50% | |
| Form 10-K Autolus Therapeutics For: Dec 31 | SEC filing · Form 10-K | -2.85% | +3.25% | |
| Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Press release | +2.07% | +0.74% | |
| Form 10-Q Autolus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -4.07% | — | |
| Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 | Press release | +0.34% | +1.34% | |
| Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | Press release | +2.20% | — | |
| Form 10-Q Autolus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -1.63% | -14.42% | |
| Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 | Press release | -0.56% | -1.49% | |
| Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates | Press release | -2.89% | -7.53% | |
| Form 10-Q Autolus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +4.07% | -2.22% | |
| Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 | Press release | +1.36% | +8.84% | |
| Form 10-K Autolus Therapeutics For: Dec 31 | SEC filing · Form 10-K | -5.23% | -1.16% | |
| Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 | Press release | +0.50% | +4.02% | |
| Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates | Press release | -2.68% | -10.48% | |
| Form 10-Q Autolus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +2.06% | -3.23% | |
| Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 | Press release | +0.22% | -3.56% | |
| Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates | Press release | -5.05% | -12.50% | |
| Form 10-Q Autolus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -2.24% | -3.42% | |
| Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 | Press release | +1.94% | +0.65% | |
| Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | Press release | +3.56% | -2.44% | |
| Form 10-Q Autolus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.60% | -8.01% | |
| Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call | Press release | -2.28% | +1.52% | |
| Form NT 10-Q Autolus Therapeutics For: May 13 | SEC filing · Form NT | -1.07% | +2.30% | |
| Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | Press release | -0.11% | -2.18% | |
| Form 10-K Autolus Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.97% | +1.94% | |
| Form 10-Q Autolus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -1.15% | -1.72% | |
| Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates | Press release | +1.72% | +16.50% |
Keep exploring
More AUTL: analyst actions → · SEC filings → · AUTL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 377 | 0.00% | 49% |
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
| Halozyme Therapeutics, Inc. (HALO) | 374 | -0.11% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.